American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
Upgrade
American Flag

Biodesix, Inc. Common Stock

BDSX Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Compensation
Government
Ownership
News

Chart provided by TradingView

BDSX historical prices
Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of BDSX by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
BDSX Stock Insider Trading Activity Follow @QuiverQuant for major insider updates

---

Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
BDSX Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
BDSX Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes in BDSX holdings by institutional investors

Insider Trading

Quarterly net insider trading by BDSX's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
View Strategy Copytrade Strategy
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions

Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.

  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More about Alpha
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More about Annual Standard Deviation
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More about Annual Volatility
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More about Beta
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More about CAGR
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More about Information Ratio
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More about Max Drawdown
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More about Sharpe Ratio
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More about Treynor Ratio
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

See Pricing
schema-2
Corporate Lobbying

Government lobbying spending instances

  • $30,000 Jul 20, 2026 Issue: Medicare/Medicaid Health Issues
  • $30,000 Apr 20, 2026 Issue: Medicare/Medicaid Health Issues
  • $30,000 Jan 20, 2026 Issue: Medicare/Medicaid Health Issues
  • $30,000 Oct 11, 2025 Issue: Medicare/Medicaid Health Issues
  • $30,000 Jul 19, 2025 Issue: Medicare/Medicaid Health Issues
  • $30,000 Apr 21, 2025 Issue: Medicare/Medicaid Health Issues
  • $30,000 Jan 21, 2025 Issue: Health Issues Medicare/Medicaid
  • $30,000 Dec 15, 2024 Issue: Medicare/Medicaid Health Issues
  • $30,000 Jul 18, 2024 Issue: Health Issues Medicare/Medicaid
  • $30,000 Jan 22, 2024 Issue: Health Issues Medicare/Medicaid
  • $30,000 Oct 20, 2023 Issue: Health Issues Medicare/Medicaid
  • $30,000 Jul 20, 2023 Issue: Health Issues Medicare/Medicaid
  • $30,000 Jan 20, 2023 Issue: Health Issues Medicare/Medicaid
  • $30,000 Oct 20, 2022 Issue: Health Issues Medicare/Medicaid
  • $30,000 Jul 20, 2022 Issue: Health Issues Medicare/Medicaid
  • $30,000 Apr 20, 2022 Issue: Medicare/Medicaid Health Issues
  • $30,000 Jan 19, 2022 Issue: Medicare/Medicaid Health Issues
  • $30,000 Oct 15, 2021 Issue: Medicare/Medicaid Health Issues
  • $30,000 Jul 20, 2021 Issue: Medicare/Medicaid Health Issues
  • $30,000 Apr 13, 2021 Issue: Health Issues Medicare/Medicaid
  • $30,000 Jan 20, 2021 Issue: Medicare/Medicaid Health Issues
  • $30,000 Jul 14, 2020 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid Health Issues
  • $60,000 Jun 27, 2020 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid Copyright/Patent/Trademark
  • $30,000 Apr 17, 2020 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid Health Issues
  • $30,000 Jan 21, 2020 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid
  • $59,235 Oct 18, 2019 Issue: Medicare/Medicaid Copyright/Patent/Trademark Medical/Disease Research/Clinical Labs
  • $58,000 Jul 18, 2019 Issue: Copyright/Patent/Trademark Medicare/Medicaid Medical/Disease Research/Clinical Labs
  • $30,000 Apr 22, 2019 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs
  • $30,000 Jan 22, 2019 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs
  • $30,000 Oct 19, 2018 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid
  • $30,000 Jul 19, 2018 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid
  • $30,000 Apr 20, 2018 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid
  • $30,000 Jan 22, 2018 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid
  • $30,000 Oct 20, 2017 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs
  • $30,000 Jul 20, 2017 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid
  • $30,000 Apr 20, 2017 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid
  • $30,000 Jan 24, 2017 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs
  • $30,000 Oct 18, 2016 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs
  • $30,000 Jul 20, 2016 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs
  • $30,000 Apr 20, 2016 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs
  • $5,000 Mar 10, 2016 Issue: Health Issues
  • $30,000 Jan 20, 2016 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs
Revolving Door

Former government officials who have lobbied for BDSX

9 former government officials from 6 congressional offices at 1 lobbying firm have lobbied for BDSX, most recently Jul 20, 2026.

  • John B. Shadegg
    Paul Edattel House Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg Formerly with John B. Shadegg · TODD STRATEGY GROUP · Jul 20, 2026
  • Daniel Todd Senate Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid Formerly Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Ad · TODD STRATEGY GROUP · Jul 20, 2026
  • Brett Guthrie
    Katherine Cotton House Staff Assistant, Legislative Correspondent, Legislative Assistant - U.S. Representative Brett Guthrie Formerly with Brett Guthrie · TODD STRATEGY GROUP · Jul 20, 2026
  • Thom Tillis
    Ted Lehman Senate Chief of Staff, Senator Tillis; Senate Judiciary Committee-Counsel, then Chief Counsel for Nominations and Senior Counsel; Senate Judiciary Committee-Staff Assistant and Legislative Assistant Formerly with Thom Tillis · TODD STRATEGY GROUP · Apr 20, 2026
  • Michael C. Burgess
    Taylor Sexton House Advisor to the Assistant Secretary for Preparedness & Response, HHS; Advisor to the Assistant Secretary of Legislation, HHS; Health Care Policy Fellow, Representative Michael Burgess Formerly with Michael C. Burgess · TODD STRATEGY GROUP · Jan 21, 2026
  • Bill Cassidy
    Jeff Lucas Senate Health Policy Advisor, Senator Bill Cassidy; Legislative Assistant/Sr. Legislative Assistant/Legislative Correspondent, Representative Larry Bucshon Formerly with Bill Cassidy · TODD STRATEGY GROUP · Oct 11, 2025
  • Bob Franks
    Kimberly Linthicum House Legislative Director, Representative Bob Franks; Legislative Correspondent, Representative Charles Taylor; Legislative Correspondent, Representative Bill Martini Formerly with Bob Franks · TODD STRATEGY GROUP · Apr 21, 2025
  • Brett Guthrie
    Eric Bergren House Chief of Staff, Rep. Brett Guthrie; Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Chief of Staff - Rep. Ron Lewis; Intern, Rep. Bill Baker Formerly with Brett Guthrie · TODD STRATEGY GROUP · Apr 21, 2025
See all 9 on the Revolving Door dashboard
Corporate Lobbying

BDSX Estimated quarterly lobbying spending

Revenue Breakdown

BDSX Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
BDSX Income Statement
BDSX Balance Sheet
BDSX Cash Flow
U.S. Patents

New BDSX patent grants

  • Patent Title: Interpretation of machine learning classifications in clinical diagnostics using shapley values and uses thereof Apr. 14, 2026
  • Patent Title: Compositions, methods and kits for diagnosis of lung cancer Mar. 11, 2025
  • Patent Title: Predictive test for patient benefit from antibody drug blocking ligand activation of the t-cell programmed cell death 1 (pd-1) checkpoint protein and classifier development methods Feb. 18, 2025
  • Patent Title: Apparatus and method for identification of primary immune resistance in cancer patients Sep. 17, 2024
  • Patent Title: Compositions, methods and kits for diagnosis of lung cancer Feb. 27, 2024
  • Patent Title: Method for predicting risk of unfavorable outcomes, e.g., in covid-19 hospitalization, from clinical characteristics and basic laboratory findings Feb. 06, 2024
  • Patent Title: Predictive test for melanoma patient benefit from interleukin-2 (il2) therapy Jul. 25, 2023
  • Patent Title: Classifier generation methods and predictive test for ovarian cancer patient prognosis under platinum chemotherapy Apr. 04, 2023
  • Patent Title: Predictive test for prognosis of myelodysplastic syndrome patients using mass spectrometry of blood-based sample Feb. 28, 2023
  • Patent Title: Antibodies targeting pulmonary nodule specific biomarkers and uses thereof Jan. 03, 2023
  • Patent Title: Method for predicting risk of unfavorable outcomes, e.g., in covid-19 hospitalization, from clinical characteristics and basic laboratory findings Oct. 18, 2022
  • Patent Title: Srm methods in alzheimer's disease and neurological disease assays Oct. 11, 2022
  • Patent Title: Compositions, methods and kits for diagnosis of lung cancer Dec. 07, 2021
  • Patent Title: Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroups Oct. 19, 2021
  • Patent Title: Predictive test for patient benefit from antibody drug blocking ligand activation of the t-cell programmed cell death 1 (pd-1) checkpoint protein and classifier development methods Mar. 16, 2021
  • Patent Title: Diagnostic test system for specific, sensitive and reproducible detection of circulating nucleic acids in whole blood Dec. 22, 2020
  • Patent Title: Compositions, methods and kits for diagnosis of lung cancer Oct. 13, 2020
  • Patent Title: Bagged filtering method for selection and deselection of features for classification Jul. 14, 2020
  • Patent Title: Selected reaction monitoring assays Jan. 14, 2020
  • Patent Title: Predictive test for aggressiveness or indolence of prostate cancer from mass spectrometry of blood-based sample Nov. 26, 2019
  • Patent Title: Blood sample separation devices and methods Sep. 24, 2019
  • Patent Title: Compositions, methods and kits for diagnosis of lung cancer Jul. 02, 2019
  • Patent Title: Early detection of hepatocellular carcinoma in high risk populations using maldi-tof mass spectrometry Feb. 26, 2019
  • Patent Title: Early detection of hepatocellular carcinoma in high risk populations using maldi-tof mass spectrometry Jul. 31, 2018
  • Patent Title: Predictive test for melanoma patient benefit from antibody drug blocking ligand activation of the t-cell programmed cell death 1 (pd-1) checkpoint protein and classifier development methods Jun. 26, 2018
  • Patent Title: Method and system for determining whether a drug will be effective on a patient with a disease Nov. 21, 2017
  • Patent Title: Predictive test for aggressiveness or indolence of prostate cancer from mass spectrometry of blood-based sample Oct. 03, 2017
  • Patent Title: Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies May. 16, 2017
  • Patent Title: Deep maldi tof mass spectrometry of complex biological samples, e.g., serum, and uses thereof Mar. 28, 2017
  • Patent Title: Method of predicting development and severity of graft-versus-host disease Feb. 07, 2017
  • Patent Title: Classification generation method using combination of mini-classifiers with regularization and uses thereof Oct. 25, 2016
  • Patent Title: Deep-maldi tof mass spectrometry of complex biological samples, e.g., serum, and uses thereof Mar. 08, 2016
  • Patent Title: Method for predicting breast cancer patient response to combination therapy Feb. 09, 2016
  • Patent Title: Treatment selection for lung cancer patients using mass spectrum of blood-based sample Dec. 15, 2015
  • Patent Title: Method and system for determining whether a drug will be effective on a patient with a disease Oct. 06, 2015
  • Patent Title: Method for predicting breast cancer patient response to endocrine therapy Dec. 16, 2014
  • Patent Title: Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents May. 06, 2014
  • Patent Title: Monitoring treatment of head and neck cancer patients with drugs targeting egfr pathway using mass spectrometry of patient samples Nov. 19, 2013
  • Patent Title: Monitoring treatment of colorectal cancer patients with drugs targeting egfr pathway using mass spectrometry of patient samples Nov. 19, 2013
  • Patent Title: Method and system for validation of mass spectrometer machine performance Jun. 18, 2013
  • Patent Title: Monitoring treatment of colorectal cancer patients with drugs targeting egfr pathway using mass spectrometry of patient samples Feb. 21, 2012
  • Patent Title: Monitoring treatment of head and neck cancer patients with drugs egfr pathway using mass spectrometry of patient samples Feb. 21, 2012
  • Patent Title: Method and system for determining whether a drug will be effective on a patient with a disease Jan. 17, 2012
  • Patent Title: Method for reliable classification of samples in clinical diagnostics using an improved method of classification Sep. 20, 2011
  • Patent Title: Monitoring treatment of cancer patients with drugs targeting egfr pathway using mass spectrometry of patient samples Mar. 15, 2011
  • Patent Title: Method and system for determining whether a drug will be effective on a patient with a disease Feb. 01, 2011
  • Patent Title: Selection of head and neck cancer patients for treatment with drugs targeting egfr pathway Jan. 11, 2011
  • Patent Title: Selection of colorectal cancer patients for treatment with drugs targeting egfr pathway Dec. 28, 2010
  • Patent Title: Selection of non-small-cell lung cancer patients for treatment with monoclonal antibody drugs targeting egfr pathway Dec. 28, 2010
  • Patent Title: Method and system for determining whether a drug will be effective on a patient with a disease Jun. 15, 2010
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded to BDSX from public contracts

BDSX News

Recent insights relating to BDSX

CNBC Recommendations

Recent picks made for BDSX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in BDSX

BDSX Analyst Ratings

BDSX Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
BDSX Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $BDSX stock a Buy, Sell, or Hold?

  • What is the price target for $BDSX stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

BDSX Top Shareholders
Shareholder
Shares Held
BDSX Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $BDSX stock?

  • Who owns the most shares of $BDSX stock?

  • What funds own $BDSX stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

BDSX Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view BDSX Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About BDSX

Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.

  • Address Louisville, CO
  • Market Cap 310.2 million
  • Employees 334
  • Industrial Classification Services-Medical Laboratories

Biodesix, Inc. Common Stock (BDSX) Historical Stock Prices

Biodesix, Inc. Common Stock (BDSX) closed at $29.40 on September 24, 2026. Over the past year its adjusted close ranged from $5.46 to $30.60. Daily prices go back to October 28, 2020, 1,483 trading days in all.

  • 1 month+4.72%
  • 3 months+46.71%
  • Year to date+332.35%
  • 1 year+250.42%
  • 3 years+2.80%
  • 5 years-82.95%
  • Max-88.52%
See every congressional and insider trade on the BDSX price chart

Quiver Premium charts BDSX's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.

Upgrade to Premium

Last 12 months, newest first

Access Raw Data Daily prices since 2014 for every ticker, through the Quiver API
DateOpenHighLowCloseAdj. CloseVolume
Sep 24, 2026 29.22 31.35 28.81 29.40 29.40 121,135
Sep 23, 2026 27.99 29.49 27.65 29.29 29.29 68,968
Sep 22, 2026 28.37 29.07 27.75 28.15 28.15 57,018
Sep 21, 2026 29.36 29.99 27.56 28.43 28.43 122,355
Sep 18, 2026 28.52 29.96 28.39 29.20 29.20 100,880
Sep 17, 2026 28.99 29.42 28.52 28.81 28.81 60,842
Sep 16, 2026 27.77 29.00 27.55 28.56 28.56 100,566
Sep 15, 2026 27.40 28.00 26.42 27.70 27.70 69,520
Sep 14, 2026 26.80 27.70 25.74 27.40 27.40 54,989
Sep 11, 2026 26.12 27.14 25.82 26.96 26.96 47,060
Sep 10, 2026 26.83 27.37 25.60 26.04 26.04 53,476
Sep 9, 2026 26.77 27.80 26.70 27.08 27.08 33,439
Sep 8, 2026 25.97 27.90 25.89 26.63 26.63 86,420
Sep 4, 2026 26.23 26.76 25.42 26.18 26.18 58,780
Sep 3, 2026 27.29 27.29 25.95 26.48 26.48 56,462
Sep 2, 2026 25.21 27.40 24.07 27.16 27.16 141,225
Sep 1, 2026 25.83 26.52 25.02 25.07 25.07 67,520
Aug 31, 2026 26.71 27.10 25.76 26.34 26.34 58,081
Aug 28, 2026 28.29 28.62 26.65 26.83 26.83 108,460
Aug 27, 2026 30.64 31.06 28.32 28.48 28.48 162,348
Aug 26, 2026 28.34 31.31 28.00 30.60 30.60 216,005
Aug 25, 2026 25.70 30.00 25.41 28.07 28.07 199,204
Aug 24, 2026 26.25 26.83 23.95 25.39 25.39 243,979
Aug 21, 2026 24.25 27.11 24.11 26.63 26.63 274,229
Aug 20, 2026 25.20 26.00 23.76 24.03 24.03 229,160
Aug 19, 2026 21.91 26.40 21.91 25.54 25.54 197,976
Aug 18, 2026 23.03 23.03 22.00 22.34 22.34 106,760
Aug 17, 2026 23.88 25.27 22.79 23.25 23.25 68,433
Aug 14, 2026 23.88 24.43 23.59 24.00 24.00 72,432
Aug 13, 2026 25.11 25.20 23.55 23.79 23.79 50,022
Aug 12, 2026 24.62 25.40 23.80 24.22 24.22 91,655
Aug 11, 2026 24.17 25.52 23.32 24.31 24.31 94,893
Aug 10, 2026 24.09 25.51 23.37 24.86 24.86 160,933
Aug 7, 2026 22.85 23.93 22.45 23.50 23.50 81,127
Aug 6, 2026 21.76 25.00 19.77 22.10 22.10 233,019
Aug 5, 2026 22.89 23.40 22.41 22.78 22.78 43,090
Aug 4, 2026 22.00 23.39 22.00 22.75 22.75 57,277
Aug 3, 2026 21.52 23.38 21.52 22.03 22.03 86,244
Jul 31, 2026 21.77 21.89 21.00 21.20 21.20 42,031
Jul 30, 2026 20.71 22.00 20.70 21.34 21.34 44,777
Jul 29, 2026 21.24 21.50 20.27 20.38 20.38 41,091
Jul 28, 2026 22.27 22.35 20.98 21.03 21.03 69,402
Jul 27, 2026 22.13 23.38 21.78 22.22 22.22 75,474
Jul 24, 2026 22.00 23.80 22.00 22.00 22.00 90,555
Jul 23, 2026 21.09 22.43 20.01 22.32 22.32 39,821
Jul 22, 2026 21.14 24.02 20.86 21.39 21.39 88,323
Jul 21, 2026 19.90 21.32 19.25 21.14 21.14 78,513
Jul 20, 2026 20.51 20.59 19.09 19.81 19.81 43,338
Jul 17, 2026 20.11 20.21 19.48 20.19 20.19 40,798
Jul 16, 2026 20.73 21.20 19.56 19.96 19.96 64,561
Jul 15, 2026 21.13 21.49 20.60 21.00 21.00 46,333
Jul 14, 2026 21.58 22.38 20.77 21.13 21.13 56,732
Jul 13, 2026 21.40 22.37 20.98 21.42 21.42 60,342
Jul 10, 2026 22.00 23.32 21.17 21.42 21.42 97,961
Jul 9, 2026 20.22 23.00 20.12 22.15 22.15 86,065
Jul 8, 2026 20.14 20.58 18.91 20.15 20.15 108,410
Jul 7, 2026 21.79 22.33 19.89 20.34 20.34 89,995
Jul 6, 2026 21.81 23.46 21.28 21.85 21.85 39,985
Jul 2, 2026 24.52 24.73 21.70 21.99 21.99 62,720
Jul 1, 2026 22.74 24.92 21.88 24.50 24.50 126,217
Jun 30, 2026 23.70 24.22 21.58 22.55 22.55 116,806
Jun 29, 2026 23.33 24.34 22.35 23.81 23.81 161,481
Jun 26, 2026 21.06 23.34 20.75 23.34 23.34 154,545
Jun 25, 2026 19.84 22.22 19.03 20.04 20.04 245,134
Jun 24, 2026 19.49 19.90 18.44 18.67 18.67 108,608
Jun 23, 2026 17.38 19.16 16.51 19.16 19.16 87,829
Jun 22, 2026 17.06 18.22 16.68 17.35 17.35 56,414
Jun 18, 2026 16.09 17.40 15.26 16.81 16.81 132,471
Jun 17, 2026 15.16 15.98 15.13 15.22 15.22 185,374
Jun 16, 2026 15.95 15.95 15.04 15.33 15.33 20,383
Jun 15, 2026 15.87 16.07 15.60 15.60 15.60 36,131
Jun 12, 2026 15.01 15.96 14.81 15.06 15.06 21,088
Jun 11, 2026 15.22 15.72 14.80 14.80 14.80 129,928
Jun 10, 2026 15.00 16.00 14.79 15.01 15.01 29,121
Jun 9, 2026 14.82 16.00 14.61 15.36 15.36 22,101
Jun 8, 2026 15.50 15.80 14.88 14.95 14.95 22,331
Jun 5, 2026 16.28 16.28 15.21 15.46 15.46 33,895
Jun 4, 2026 15.91 16.71 15.91 16.50 16.50 41,729
Jun 3, 2026 15.53 16.10 15.28 16.10 16.10 20,853
Jun 2, 2026 15.35 15.79 15.04 15.44 15.44 47,199
Jun 1, 2026 15.99 16.42 15.26 15.27 15.27 38,533
May 29, 2026 16.24 17.21 15.81 16.32 16.32 106,769
May 28, 2026 15.08 16.47 15.08 15.99 15.99 120,554
May 27, 2026 14.62 15.11 14.42 14.81 14.81 43,030
May 26, 2026 15.10 15.10 14.24 14.81 14.81 29,965
May 22, 2026 15.04 15.43 14.72 14.93 14.93 30,179
May 21, 2026 14.44 15.44 14.44 15.18 15.18 17,777
May 20, 2026 14.04 14.57 13.90 14.37 14.37 13,642
May 19, 2026 14.14 14.48 13.59 13.94 13.94 36,993
May 18, 2026 14.09 14.60 13.58 14.25 14.25 29,665
May 15, 2026 14.43 14.48 13.50 14.17 14.17 45,131
May 14, 2026 14.73 14.88 14.05 14.76 14.76 30,540
May 13, 2026 15.81 15.81 14.52 14.64 14.64 53,591
May 12, 2026 16.15 16.50 15.23 15.75 15.75 42,319
May 11, 2026 15.18 16.41 14.81 16.11 16.11 109,000
May 8, 2026 15.47 15.52 14.79 15.32 15.32 73,252
May 7, 2026 14.94 15.85 14.77 15.47 15.47 79,476
May 6, 2026 14.76 15.44 14.38 15.00 15.00 108,831
May 5, 2026 13.50 15.51 13.32 14.94 14.94 449,510
May 4, 2026 10.89 12.20 10.73 11.27 11.27 115,381
May 1, 2026 10.95 11.43 10.53 11.08 11.08 27,941
Apr 30, 2026 9.76 11.39 9.76 10.98 10.98 101,818
Apr 29, 2026 9.87 10.18 9.43 9.84 9.84 55,175
Apr 28, 2026 10.18 10.37 9.95 9.95 9.95 27,054
Apr 27, 2026 10.80 10.80 9.95 10.12 10.12 31,458
Apr 24, 2026 10.16 10.96 10.00 10.64 10.64 49,540
Apr 23, 2026 11.56 11.56 9.86 9.96 9.96 118,872
Apr 22, 2026 13.08 13.55 11.06 11.58 11.58 126,149
Apr 21, 2026 13.34 13.63 12.72 12.85 12.85 36,565
Apr 20, 2026 13.13 13.55 13.00 13.17 13.17 24,898
Apr 17, 2026 13.02 13.80 13.00 13.14 13.14 30,500
Apr 16, 2026 12.75 13.81 12.64 13.31 13.31 50,990
Apr 15, 2026 12.25 13.05 12.25 12.66 12.66 64,529
Apr 14, 2026 13.38 13.50 12.13 12.14 12.14 74,592
Apr 13, 2026 12.80 13.49 12.80 13.36 13.36 27,962
Apr 10, 2026 13.43 13.51 12.77 13.13 13.13 80,699
Apr 9, 2026 14.07 14.40 12.78 13.32 13.32 62,539
Apr 8, 2026 14.80 14.98 14.12 14.25 14.25 38,888
Apr 7, 2026 15.24 15.34 14.27 14.53 14.53 49,779
Apr 6, 2026 15.10 16.26 15.10 15.36 15.36 97,164
Apr 2, 2026 14.73 15.49 14.51 15.07 15.07 41,850
Apr 1, 2026 14.48 15.20 14.44 14.76 14.76 26,550
Mar 31, 2026 14.00 14.74 13.58 14.50 14.50 31,412
Mar 30, 2026 14.14 14.72 13.41 13.79 13.79 56,317
Mar 27, 2026 14.65 14.65 13.56 14.21 14.21 65,836
Mar 26, 2026 14.85 15.50 14.59 14.60 14.60 59,376
Mar 25, 2026 15.56 16.02 14.77 15.15 15.15 83,112
Mar 24, 2026 14.51 16.10 14.51 15.54 15.54 81,836
Mar 23, 2026 14.74 15.63 14.50 14.69 14.69 86,213
Mar 20, 2026 16.80 17.00 14.63 14.88 14.88 91,915
Mar 19, 2026 15.79 17.00 15.59 16.30 16.30 101,066
Mar 18, 2026 16.26 16.72 15.99 16.09 16.09 65,776
Mar 17, 2026 17.24 17.90 16.20 16.59 16.59 108,552
Mar 16, 2026 17.90 18.81 17.13 17.29 17.29 106,425
Mar 13, 2026 19.30 20.20 17.03 17.88 17.88 119,444
Mar 12, 2026 19.04 20.21 18.90 19.15 19.15 121,227
Mar 11, 2026 18.51 19.25 18.21 19.07 19.07 136,850
Mar 10, 2026 19.53 19.58 18.17 18.72 18.72 107,732
Mar 9, 2026 18.61 19.71 18.07 19.40 19.40 210,388
Mar 6, 2026 15.84 18.99 15.24 18.78 18.78 385,891
Mar 5, 2026 15.32 15.86 14.55 15.86 15.86 149,632
Mar 4, 2026 15.62 15.87 14.61 15.30 15.30 134,292
Mar 3, 2026 15.68 16.35 14.73 15.50 15.50 185,569
Mar 2, 2026 14.52 16.63 14.23 15.75 15.75 249,567
Feb 27, 2026 14.79 17.40 14.54 15.33 15.33 377,967
Feb 26, 2026 12.91 14.22 12.36 14.22 14.22 128,423
Feb 25, 2026 13.08 13.37 12.26 12.93 12.93 97,665
Feb 24, 2026 12.68 13.30 11.95 13.02 13.02 109,365
Feb 23, 2026 13.00 13.32 12.05 12.77 12.77 99,179
Feb 20, 2026 12.90 14.17 12.30 13.19 13.19 159,539
Feb 19, 2026 12.51 12.75 11.80 12.75 12.75 55,206
Feb 18, 2026 12.58 13.75 11.97 12.57 12.57 121,617
Feb 17, 2026 11.53 12.79 10.92 12.78 12.78 127,759
Feb 13, 2026 10.85 13.63 10.51 11.45 11.45 332,395
Feb 12, 2026 10.38 11.00 9.83 10.84 10.84 117,740
Feb 11, 2026 10.40 10.58 9.90 10.35 10.35 86,859
Feb 10, 2026 10.06 10.79 9.88 10.40 10.40 121,185
Feb 9, 2026 10.33 10.68 9.81 9.93 9.93 76,852
Feb 6, 2026 10.10 10.84 9.95 10.38 10.38 83,068
Feb 5, 2026 10.05 10.41 9.79 9.96 9.96 57,203
Feb 4, 2026 11.05 11.57 9.87 10.30 10.30 76,281
Feb 3, 2026 10.42 11.50 10.35 11.03 11.03 197,902
Feb 2, 2026 9.91 10.55 9.00 10.29 10.29 167,846
Jan 30, 2026 9.67 10.25 8.69 10.17 10.17 249,882
Jan 29, 2026 10.22 10.50 9.14 9.66 9.66 176,557
Jan 28, 2026 11.34 11.49 9.61 10.33 10.33 210,438
Jan 27, 2026 10.41 11.39 10.31 11.08 11.08 294,300
Jan 26, 2026 11.69 12.70 10.02 10.09 10.09 499,773
Jan 23, 2026 11.22 12.46 11.16 11.74 11.74 498,663
Jan 22, 2026 10.52 11.38 10.52 11.10 11.10 450,936
Jan 21, 2026 9.03 11.90 8.50 10.92 10.92 1,038,219
Jan 20, 2026 7.94 9.10 7.65 8.92 8.92 417,095
Jan 16, 2026 8.40 8.71 7.77 7.88 7.88 408,569
Jan 15, 2026 9.08 9.40 8.21 8.33 8.33 699,312
Jan 14, 2026 9.88 10.00 8.11 8.59 8.59 877,542
Jan 13, 2026 7.95 9.90 7.26 9.88 9.88 2,507,235
Jan 12, 2026 7.00 9.83 6.94 8.08 8.08 75,528,666
Jan 9, 2026 5.70 5.86 5.26 5.46 5.46 43,495
Jan 8, 2026 5.86 6.20 5.57 5.58 5.58 63,431
Jan 7, 2026 6.01 6.18 5.70 5.96 5.96 35,713
Jan 6, 2026 6.18 6.34 5.61 6.03 6.03 97,470
Jan 5, 2026 6.47 6.49 5.97 6.23 6.23 141,702
Jan 2, 2026 6.76 6.92 6.37 6.46 6.46 23,604
Dec 31, 2025 6.68 6.80 6.60 6.80 6.80 29,846
Dec 30, 2025 6.81 6.81 6.57 6.72 6.72 36,001
Dec 29, 2025 6.76 6.88 6.54 6.86 6.86 72,681
Dec 26, 2025 6.88 6.88 6.60 6.82 6.82 34,358
Dec 24, 2025 6.63 6.89 6.56 6.82 6.82 39,897
Dec 23, 2025 6.73 7.03 6.64 6.75 6.75 26,678
Dec 22, 2025 6.79 7.03 6.65 6.81 6.81 43,939
Dec 19, 2025 7.11 7.79 6.30 6.69 6.69 203,186
Dec 18, 2025 7.63 8.03 6.90 7.10 7.10 151,236
Dec 17, 2025 7.91 7.96 7.51 7.54 7.54 26,314
Dec 16, 2025 7.94 8.12 7.55 7.90 7.90 96,073
Dec 15, 2025 8.20 8.20 7.51 7.52 7.52 30,897
Dec 12, 2025 8.00 8.19 7.79 7.85 7.85 30,764
Dec 11, 2025 7.96 8.10 7.77 8.02 8.02 26,935
Dec 10, 2025 8.26 8.26 8.05 8.14 8.14 38,703
Dec 9, 2025 7.76 8.38 7.43 8.32 8.32 51,313
Dec 8, 2025 7.72 7.90 7.24 7.79 7.79 240,248
Dec 5, 2025 8.36 8.69 7.62 7.67 7.67 97,706
Dec 4, 2025 8.03 8.62 8.03 8.54 8.54 59,740
Dec 3, 2025 7.97 8.33 7.72 8.14 8.14 59,376
Dec 2, 2025 7.82 7.98 7.68 7.83 7.83 17,121
Dec 1, 2025 8.08 8.14 7.76 7.79 7.79 46,224
Nov 28, 2025 7.86 8.32 7.60 8.28 8.28 16,406
Nov 26, 2025 7.79 7.98 7.45 7.87 7.87 37,432
Nov 25, 2025 7.31 7.74 7.22 7.74 7.74 29,026
Nov 24, 2025 6.89 7.44 6.57 7.34 7.34 25,483
Nov 21, 2025 6.57 6.98 6.42 6.83 6.83 26,079
Nov 20, 2025 7.00 7.20 6.40 6.51 6.51 87,516
Nov 19, 2025 7.28 7.44 6.81 6.90 6.90 18,580
Nov 18, 2025 7.84 7.94 6.69 7.18 7.18 230,511
Nov 17, 2025 8.03 8.52 7.92 7.92 7.92 41,877
Nov 14, 2025 7.75 8.43 7.50 8.00 8.00 81,029
Nov 13, 2025 7.99 7.99 7.42 7.90 7.90 63,691
Nov 12, 2025 8.18 8.47 7.88 7.95 7.95 55,111
Nov 11, 2025 7.59 8.36 7.59 8.34 8.34 54,269
Nov 10, 2025 7.62 7.73 7.32 7.54 7.54 51,372
Nov 7, 2025 7.69 7.73 7.16 7.73 7.73 52,048
Nov 6, 2025 8.29 8.68 7.65 7.79 7.79 205,008
Nov 5, 2025 7.44 8.75 7.15 8.60 8.60 252,203
Nov 4, 2025 7.06 7.79 6.45 7.60 7.60 240,983
Nov 3, 2025 6.76 7.15 6.19 6.34 6.34 117,829
Oct 31, 2025 6.52 7.09 6.43 6.83 6.83 44,627
Oct 30, 2025 6.47 6.94 6.33 6.57 6.57 65,295
Oct 29, 2025 6.59 6.81 6.22 6.54 6.54 74,777
Oct 28, 2025 6.58 7.06 6.34 6.55 6.55 49,947
Oct 27, 2025 6.74 6.93 6.40 6.65 6.65 75,792
Oct 24, 2025 6.50 6.96 6.22 6.73 6.73 100,648
Oct 23, 2025 5.95 6.75 5.91 6.43 6.43 236,706
Oct 22, 2025 6.99 7.23 5.84 6.00 6.00 4,368,135
Oct 21, 2025 6.58 6.90 6.56 6.83 6.83 38,649
Oct 20, 2025 6.71 6.75 6.34 6.62 6.62 77,168
Oct 17, 2025 6.94 7.00 6.33 6.42 6.42 89,680
Oct 16, 2025 7.42 7.57 6.81 6.95 6.95 55,562
Oct 15, 2025 7.77 7.78 7.26 7.42 7.42 75,015
Oct 14, 2025 7.37 7.81 7.25 7.79 7.79 31,065
Oct 13, 2025 7.35 7.74 7.26 7.40 7.40 34,679
Oct 10, 2025 7.85 7.97 7.26 7.32 7.32 44,719
Oct 9, 2025 7.71 8.20 7.51 7.83 7.83 37,329
Oct 8, 2025 7.27 7.93 7.11 7.75 7.75 46,796
Oct 7, 2025 7.52 7.81 7.20 7.30 7.30 33,673
Oct 6, 2025 7.75 7.95 7.40 7.54 7.54 33,540
Oct 3, 2025 7.70 7.87 7.54 7.74 7.74 41,675
Oct 2, 2025 7.73 7.77 7.63 7.70 7.70 31,201
Oct 1, 2025 7.47 7.76 7.36 7.67 7.67 27,733
Sep 30, 2025 7.72 7.88 7.35 7.55 7.55 40,349
Sep 29, 2025 7.75 8.07 7.66 7.74 7.74 23,449
Sep 26, 2025 8.10 8.42 7.58 7.75 7.75 54,145
Sep 25, 2025 8.18 8.34 7.89 8.01 8.01 47,769
Sep 24, 2025 7.91 8.61 7.91 8.39 8.39 95,895

Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.

Need daily prices for every ticker, in code?

The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.

Explore the Quiver API
Biodesix, Inc. Common Stock Executive Compensation

We estimate that -- received a compensation of -- in --, making them the highest paid executive at BDSX, per a recent SEC DEF 14A filing.



Name
Role
Salary
Bonus
Stock/Option Awards
Total Compensation